In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plus Orthopedics AG

Division of Smith & Nephew PLC
www.plusorthopedics.com

Latest From Plus Orthopedics AG

Obstacles Ahead for TJR Market

With few new treatment options on the horizon for patients suffering from joint pain associated with hip and knee osteoarthritis, it should come as no surprise that the business of joint replacement is booming and will continue to do so for the foreseeable future. Even in the current economic environment where elective joint replacement procedures are likely to slow down, there has not (yet) been a significant impact on implant sales.The industry admits it is not immune to the global economic crisis, at least in the short term. However, over the long haul, the general consensus is that this market will remain strong owing to solid growth in the patient pool.
Medical Device

Challenges Ahead for TJR Market

A reprint of a feature in the February 2009 issue of Medtech Insight. With few new treatment options on the horizon for patients suffering from joint pain associated with hip and knee osteoarthritis, it should come as no surprise that the business of joint replacement is booming and will continue to do so for the foreseeable future. Even in the current economic environment where elective joint replacement procedures are likely to slow down, there has not (yet) been a significant impact on implant sales.The industry admits it is not immune to the global economic crisis, at least in the short term. However, over the long haul, the general consensus is that this market will remain strong owing to solid growth in the patient pool.

TJR Market: Pressure on All Fronts

Aging baby boomers spell good news for the $11 billion total joint replacement industry. The bad news is the economic burden this highly active population, the major recipients of joint replacement surgeries, will place on the nation's health care system. With the number of TJR procedures expected to soar in the coming years, it's no surprise that CMS is focused on reducing the costs of TJR procedures. And that's bad news for the orthopedic surgeons who perform them.
Medical Device

Plus Orthopedics: The Story Behind the Deal

Even by the standards of today's medical device world, the acquisition last year of Plus Orthopedics Holdings by Smith & Nephew was impressive. Perhaps it was the deal's value: by any measure, one billion Swiss francs (or just under $900 million) simply has a nice ring to it. Perhaps it was the deal's European provenance: rarely in Europe do small start-ups grow to a size to justify such a valuation. But if the deal was anything but typical, the story behind Plus seems almost textbook.
Medical Device Leadership
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Plus Endoprothetik AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Smith & Nephew PLC
  • Senior Management
  • Robert Riedweg, PhD, CEO
  • Contact Info
  • Plus Orthopedics AG
    Phone: (41) 41 798 41 11
    Erlenstrasse 4a
    Rotkreuz, 6343
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register